Curated News
By: NewsRamp Editorial Staff
October 06, 2026
Okogen Gets CDSCO Nod for Treyegen™ Phase 1/2 Conjunctivitis Study
TLDR
- Okogen gains CDSCO authorization for its EMERALD Phase 1/2 trial, positioning Treyegen as a first-in-class dual-action conjunctivitis therapy in India.
- The EMERALD study will enroll over 300 patients to assess safety, pharmacokinetics, antiviral and antibacterial activity, and clinical efficacy of Treyegen.
- Treyegen could simplify treatment for acute infectious conjunctivitis, offering a single therapy that addresses viral and bacterial causes and reduces ocular redness.
- Treyegen combines ranpirnase, tobramycin, and oxymetazoline into one eye therapy, potentially tackling both viral and bacterial conjunctivitis simultaneously.
Impact - Why it Matters
This news matters because acute infectious conjunctivitis, commonly known as pink eye, is a highly contagious condition that affects millions of people annually, leading to significant discomfort, missed work and school days, and substantial healthcare costs. Current treatments often require guesswork because clinicians must determine whether the infection is viral or bacterial before prescribing, and there is no single therapy that addresses both. Treyegen™ (OKG-0303) could change that paradigm by offering a single formulation that targets both types of infection while also reducing redness. If successful, this therapy could streamline treatment, improve patient outcomes, and reduce the overuse of antibiotics. Moreover, the CDSCO authorization validates Okogen's host-directed antiviral platform and opens the door to further clinical development in a populous country with a high burden of infectious diseases. The EMERALD study's data, expected later this year, will be closely watched as a potential breakthrough in ophthalmology and as a proof of concept for ranpirnase across other therapeutic areas.
Summary
Okogen, Inc., a clinical-stage biotechnology company focused on innovative therapies for infectious diseases, has received authorization from the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, to conduct the EMERALD study. This Phase 1/2 clinical trial will evaluate Treyegen™ (OKG-0303) for the treatment of acute infectious conjunctivitis. The study is a significant step forward for Okogen's host-directed antiviral platform, with the potential to address a common yet challenging eye infection that affects millions worldwide.
The EMERALD study is designed to enroll more than 300 patients and will assess safety, pharmacokinetics, virologic and microbiologic activity, and clinical efficacy, with data expected later this year. Treyegen™ (OKG-0303) is a proprietary ophthalmic formulation that combines ranpirnase, a host-directed antiviral; tobramycin, a broad-spectrum antibacterial; and oxymetazoline, which reduces ocular redness, into a single investigational therapy. This differentiated approach aims to simplify treatment decisions by providing physicians with a comprehensive option that targets both viral and bacterial forms of acute infectious conjunctivitis. For full details, click here.
Okogen is advancing ranpirnase-based therapies across four therapeutic pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. The company positions ophthalmology as the lead clinical proving ground for its platform, with the goal of applying insights and capabilities across a broader portfolio of antiviral therapies. For more information, visit www.okogen.com.
Source Statement
This curated news summary relied on content distributed by Reportable. Read the original source here, Okogen Gets CDSCO Nod for Treyegen™ Phase 1/2 Conjunctivitis Study
